Skip to main
MLYS
MLYS logo

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. has demonstrated promising results from its clinical trials for lorundrostat, showing a robust placebo-adjusted reduction in blood pressure by 9.1 mmHg after six weeks and 11.7 mmHg after twelve weeks, indicating its potential effectiveness in treating uncontrolled and resistant hypertension. The favorable safety profile, with a low hyperkalemia rate of 1.1%, enhances the product's commercial viability and supports its differentiated position in the market. Given these encouraging outcomes and the potential for lorundrostat to achieve a significant blood pressure reduction of 8-12 mmHg, the outlook for Mineralys Therapeutics remains positive, suggesting substantial upside potential for the stock.

Bears say

Mineralys Therapeutics Inc. reported a significant net loss of $48.9 million for the fourth quarter of 2024 and a total net loss of $177.8 million for the full year, indicating substantial financial challenges. The company's investment outlook is burdened by critical risks, including the potential failure of its lead product candidate, lorundrostat, to meet projected peak commercial revenue due to limitations in market size, penetration rates, and pricing strategies. Additionally, there are concerns regarding the company's ability to secure sufficient capital to sustain operations and support ongoing program development and commercialization efforts.

MLYS has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 8 analysts, MLYS has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.